lyl797
lyell immunopharmaceutical
['lyl797', 'lyell ']
lyell immunopharma presents first in human trial design of lyl797 at esmo 2022 - san francisco, calif., sept. 12, 2022 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a clinical stage t-cell reprogramming company dedicated to developing c... 
CEO Of Digital Media Online